Skip to main content
. 2017 Jul 27;8(35):59677–59689. doi: 10.18632/oncotarget.19641

Table 2. Treatment-Related AEs (Grade 1-4/3-4) for PD-1/PD-L1 antibodies vs. docetaxel.

AEs (Grade 1–4/3-4) PD1/PD-L1antibody DOX Heterogeneity P and I2 RR (95%CI) Z value P value
any events(G1-4) 1201/1851 1464/1728 0.421 0.0% 0.77(0.74,0.79) 13.38 0.000
 (G3-4) 284/1851 751/1728 0.000 91.0% 0.33(0.22,0.51) 5.03 0.000
Nausea(G1-4) 239/1851 358/1728 0.047 55.0% 0.58(0.46,0.75) 4.28 0.000
 (G3-4) 10/1851 8/1728 0.827 0.0% 0.15(0.48,2.77) 0.31 0.756
Febrile neutropenia(G1-4) 1/1851 146/1728 0.994 0.0% 0.02(0.01,0.06) 7.06 0.000
 (G3-4) 1/1851 144/1728 0.994 0.0% 0.02(0.01,0.07) 7.03 0.000
Diarrhea(G1-4) 182/1851 371/1728 0.032 59.0% 0.41(0.31,0.55) 5.98 0.000
 (G3-4) 9/1851 35/1728 0.800 0.0% 0.26(0.13,0.52) 3.79 0.000
Neutropenia(G1-4) 16/1851 322/1728 0.051 55.0% 0.04(0.02,0.10) 6.74 0.000
 (G3-4) 3/1851 246/1728 0.684 0.0% 0.02(0.01,0.05) 9.04 0.000
Anemia(G1-4) 110/1851 319/1728 0.001 77.0% 0.25(0.14,0.42) 5.01 0.000
 (G3-4) 19/1709 54/1593 0.658 0.0% 0.34(0.20,0.56) 4.17 0.000
Fatigue(G1-4) 354/1851 524/1728 0.225 28.0% 0.63(0.56,0.71) 7.65 0.000
 (G3-4) 32/1851 72/1728 0.281 20.0% 0.42(0.28,0.63) 4.17 0.000
Rash(G1-4) 105/1100 44/1015 0.070 57.0% 2.01(1.14,3.51) 2.43 0.020
 (G3-4) 3/1100 2/1015 0.540 0.0% 1.17(0.31,4.42) 0.24 0.810
Alopecia(G1-4) 11/1851 551/1728 0.900 0.0% 0.02(0.01,0.04) 13.31 0.000-
 (G3-4) 0/1851 7/1728 0.997 0.0% 0.25 (0.06,0.99) 1.98 0.048
Colitis(G1-4) 11/1242 0/1150 0.999 0.0% 4.99 (1.45,17.11) 2.55 0.011
 (G3-4) 7/1242 0/1150 0.994 0.0% 3.55 (0.88,14.28) 1.78 0.075
Hypothyroidism(G1-4) 87/1242 2/1150 0.974 0.0% 23.36(8.04-67.90) 5.79 0.000
Hyperthyroidism(G1-4) 36/969 6/886 0.765 0.0% 5.10(2.23-11.68) 3.85 0.000
Pneumonitis(G1-4) 62/1242 18/1150 0.653 0.0% 3.19(1.90-5.34) 4.40 0.000
interstitial lung disease(G1-4) 5/1100 5/1015 0.607 0.0% 0.93(0.29-2.87) 0.13 0.893